The individual researcin projects comprising this Endometrial Cancer SPORE require the procurement, processing, and microscopic analysis of normal endometrial tissues and endometrial cancers from surgical hysterectomy specimens. In addition, several of the SPORE projects propose animal model studies that will require histological processing and careful pathological assessment of rat and mouse uterine tissues. In this proposal, the Core will continue its active commitment to high-quality translational research in endometrial cancer that began with initial SPORE funding in 2003. Since 2003, the Gore has provided endometrial tissues and pathological expertise to 20 different investigators, 9 of which were outside of MDACC. These collaborations beginning in 2003 have resulted in 57 publications and 2 NIH/NCI R01 grants in which Core materials from endometrial cancer patients were used. Importantly, the Core enthusiastically supports trainees in learning translational research;23 different trainees (9 different trainee mentors) have been provided with Core resources and expertise since 2003. The following Specific Aims are proposed for this Core.
Aim 1 is to maintain a frozen and paraffinembedded tissue repository of endometrial cancers, hyperplasias, and normal endometrial samples.
Aim 2 is to provide pathological review for all clinical specimens utilized in the SPORE projects and for related clinical trials and to provide histopathological technical services as necessary. This includes histological processing and microscopic evaluation of uterine tissues derived from the proposed mouse and rat experiments in several projects.
Aim 3 is to establish a blood/urine/ascites fluid collection from patients undergoing hysterectomy for endometrial cancer and endometrial hyperplasia and from patients undergoing hysterectomy for non-endometrial pathology (uterine leiomyomas, cervix dysplasia, endometriosis). Such fluids will provide resources for the future testing of putative diagnostic/prognostic markers for endometrial cancer.
Aim 4 is to create and maintain a database for all frozen and paraffin-embedded endometrial tissues and fluids collected by the Core.
The Pathology Core collaborates with all SPORE project investigators to aid in translational research for endometrial cancer. The Core provides endometrial cancer tissues, endometrial cancer slides, and technical expertise in the microscopic interpretation of experiments utilizing immunohistochemistry.
|Suidan, Rudy S; Sun, Charlotte C; Cantor, Scott B et al. (2018) Three Lymphadenectomy Strategies in Low-Risk Endometrial Carcinoma: A Cost-Effectiveness Analysis. Obstet Gynecol 132:52-58|
|Chu, Yiyi; Yuan, Ying (2018) A Bayesian basket trial design using a calibrated Bayesian hierarchical model. Clin Trials 15:149-158|
|Gharpure, Kshipra M; Pradeep, Sunila; Sans, Marta et al. (2018) FABP4 as a key determinant of metastatic potential of ovarian cancer. Nat Commun 9:2923|
|Crumley, Suzanne; Kurnit, Katherine; Hudgens, Courtney et al. (2018) Identification of a subset of microsatellite-stable endometrial carcinoma with high PD-L1 and CD8+ lymphocytes. Mod Pathol :|
|Mitamura, T; Pradeep, S; McGuire, M et al. (2018) Induction of anti-VEGF therapy resistance by upregulated expression of microseminoprotein (MSMP). Oncogene 37:722-731|
|Aslan, Ozlem; Cremona, Mattia; Morgan, Clare et al. (2018) Preclinical evaluation and reverse phase protein Array-based profiling of PI3K and MEK inhibitors in endometrial carcinoma in vitro. BMC Cancer 18:168|
|Yuan, Jiao; Hu, Zhongyi; Mahal, Brandon A et al. (2018) Integrated Analysis of Genetic Ancestry and Genomic Alterations across Cancers. Cancer Cell 34:549-560.e9|
|Hsieh, Hui-Ju; Zhang, Wei; Lin, Shu-Hong et al. (2018) Systems biology approach reveals a link between mTORC1 and G2/M DNA damage checkpoint recovery. Nat Commun 9:3982|
|Bowser, Jessica L; Phan, Luan H; Eltzschig, Holger K (2018) The Hypoxia-Adenosine Link during Intestinal Inflammation. J Immunol 200:897-907|
|Peng, Xinxin; Xu, Xiaoyan; Wang, Yumeng et al. (2018) A-to-I RNA Editing Contributes to Proteomic Diversity in Cancer. Cancer Cell 33:817-828.e7|
Showing the most recent 10 out of 578 publications